Marksans Pharma Limited (NSE:MARKSANS)
321.60
-8.10 (-2.46%)
Aug 31, 2026, 3:29 PM IST
Marksans Pharma Revenue
Marksans Pharma had revenue of 8.41B INR in the quarter ending June 30, 2026, with 35.61% growth. This brings the company's revenue in the last twelve months to 31.72B, up 19.59% year-over-year. In the fiscal year ending March 31, 2026, Marksans Pharma had annual revenue of 29.51B with 12.51% growth.
Revenue (ttm)
31.72B
Revenue Growth
+19.59%
P/S Ratio
4.59
Revenue / Employee
18.82M
Employees
1,685
Market Cap
145.74B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 29.51B | 3.28B | 12.51% |
| Mar 31, 2025 | 26.23B | 4.45B | 20.46% |
| Mar 31, 2024 | 21.77B | 3.25B | 17.56% |
| Mar 31, 2023 | 18.52B | 3.61B | 24.23% |
| Mar 31, 2022 | 14.91B | 1.15B | 8.33% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 599.11B |
| Zydus Lifesciences | 285.92B |
| Apollo Hospitals Enterprise | 264.30B |
| Divi's Laboratories | 112.30B |
| Alembic Pharmaceuticals | 77.84B |
| Indegene | 38.13B |
| Syngene International | 36.00B |
| NATCO Pharma | 34.85B |
Marksans Pharma News
- 18 days ago - Marksans Pharma Transcript: Q1 26/27 - Transcripts
- 18 days ago - Marksans Pharma Quarterly report: Q1 2027 - Filings
- 18 days ago - Marksans Pharma Slides: Q1 2027 - Filings
- 7 weeks ago - Marksans Pharma to acquire ABCnow GmbH for €892,384 - Business Upturn
- 2 months ago - Marksans Pharma announces ₹0.90 per share final dividend for FY26 - Business Upturn
- 2 months ago - Marksans Pharma announces 90% final dividend ahead of AGM - Business Upturn
- 2 months ago - Marksans Pharma submits machine-readable financial results for March 2026 - Business Upturn
- 2 months ago - Marksans Pharma launches campaign to prevent transfer of unclaimed dividends - Business Upturn